Working… Menu
Trial record 4 of 180 for:    RET

Ponatinib in Advanced NSCLC w/ RET Translocations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01813734
Recruitment Status : Completed
First Posted : March 19, 2013
Last Update Posted : November 9, 2018
Information provided by (Responsible Party):
Alice Shaw, Massachusetts General Hospital

Brief Summary:

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug is being studied.

It has been found that some people with NSCLC have a change (mutation) in a certain gene called the RET gene. This mutated gene may help cancer cells grow. Only participants with a RET mutation will be allowed to participate. In this study, investigators are testing the strategy of using a study drug designed to inhibit or shut off growth signals that results from the mutated RET gene.

Ponatinib is an anti-cancer drug that has been used in research studies for other types of cancer. Ponatinib blocks several growth signals in cancer cells, including RET. In this research study, investigators are looking to see whether ponatinib is effective and safe in treating NSCLC harboring RET rearrangements.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Drug: Ponatinib Phase 2

Detailed Description:

Participants in this research study will be asked to undergo some screening tests or procedures to confirm that eligibility. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that participants do not take part in the research study. These tests and procedures include the following: medical history, vital signs, physical exam, performance status, electrocardiogram, echocardiogram, routine blood tests, pregnancy test and an assessment of tumor by CT or MRI. If these tests show that a participant is eligible to participate in the research study, he/she will begin the study treatment. If a patient does not meet the eligibility criteria, he/she will not be able to participate in this research study.

Participants will take the study drug once a day, every day of the cycle. Each treatment cycle lasts 28 days (4 weeks). Participants will be given a drug diary to record the drug they take each day. The diary will also include special instructions for taking the study drug.

For cycles 1-20, participants will visit the clinic to have tests and procedures done at the time points listed here: On Day 1-physical exam, vital signs, performance status, electrocardiogram, routine blood tests, pharmacokinetic test, clinical exam and assessment of tumor. On day 15 of cycle 1-vital signs, routine blood tests and clinical exam.

For cycles 11 and on, participants will visit the clinic every 6 weeks. Some of these visits will happen on Day 1 of the cycle and some of these visits will happen on Day 15 of the cycle. At each visit, the following tests and procedures will be done: physical exam, vital signs, performance status, electrocardiogram, routine blood tests, clinical exam, and an assessment of your tumor.

Participants will visit the clinic when their study doctor takes them off study drug permanently. They will also visit the clinic 30 days after stop taking the study drug. The following tests and procedures will be done: physical exam, vital signs, performance status, electrocardiogram, routine blood tests, pregnancy test, clinical exam and a tumor assessment.

Investigators would also like to keep track of participant's medical condition for two years after their first study dose. Investigators will contact participants by telephone every 3 months. If participants still come to the clinic, visits might be used as contact.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Study Start Date : September 2013
Actual Primary Completion Date : June 2018
Actual Study Completion Date : August 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ponatinib Treatment Arm
Ponatinib 30 mg PO daily
Drug: Ponatinib
28 day cycle

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: 2 years ]
    To evaluate the overall response rate (ORR) of ponatinib in RET-positive NSCLC as assessed by RECIST criteria

Secondary Outcome Measures :
  1. Disease Control Rate [ Time Frame: 2 years ]
  2. Progression-Free Survival [ Time Frame: 2 years ]
  3. 1 Year Overall Survival Rate [ Time Frame: 1 year ]
  4. Number of participants with adverse events [ Time Frame: 2 years ]
    To determine the safety and tolerability of ponatinib in patients with RET translocation positive NSCLC

  5. Plasma concentrations of ponatinib [ Time Frame: 2 years ]
    To determine the plasma pharmacokinetics of ponatinib

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced NSCLC
  • Molecular confirmation of a RET translocation
  • At least one measurable lesion as defined by RECIST
  • No restriction on number of prior therapies
  • Estimated life expectancy of at least 12 weeks
  • Able to swallow and retain orally administered medication
  • Must agree to use an effective form of contraception from enrollment through 30 days after the end of study treatment
  • Willingness and ability to comply with scheduled visits and study procedures

Exclusion Criteria:

  • Clinically significant gastrointestinal abnormalities
  • Pregnant or breastfeeding
  • Major surgery within 28 days of initiating therapy
  • History of CNS disease (Note: Participants with brain metastases will be eligible if treated appropriately and if they remain clinically stable).
  • Anti-cancer therapy within 3 weeks
  • History of significant bleeding disorder unrelated to cancer
  • History of acute pancreatitis within 1 year of study entry or history of chronic pancreatitis
  • History of alcohol abuse
  • Uncontrolled hypertriglyceridemia
  • History of arterial thrombotic events (myocardial infarction, stroke or peripheral vascular disease).
  • Uncontrolled hypertension
  • Taking medications that are known to be associated with Torsades de Pointes
  • Ongoing active infection
  • Diagnosed with or received anti-cancer therapy for another primary malignancy within 3 years prior to entry (except for non-melanoma skin cancer or in situ cancers)
  • Any condition or illness tha could compromise patient safety or interfere with the evaluation of the drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01813734

Layout table for location information
United States, California
University of California, Irvine
Orange, California, United States, 92868
United States, Maryland
University of Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02115
United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States
United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Massachusetts General Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Alice Shaw, Principal Investigator, Massachusetts General Hospital Identifier: NCT01813734     History of Changes
Other Study ID Numbers: 13-103
First Posted: March 19, 2013    Key Record Dates
Last Update Posted: November 9, 2018
Last Verified: November 2018
Keywords provided by Alice Shaw, Massachusetts General Hospital:
RET gene mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action